Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SALUTENSIN vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Salutensin is a combination of two antihypertensive agents: hydroflumethiazide, a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption; and reserpine, a Rauwolfia alkaloid that depletes catecholamines (norepinephrine, dopamine) from presynaptic nerve terminals by irreversibly blocking vesicular monoamine transporter (VMAT), leading to decreased peripheral vasoconstriction and heart rate.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Hypertension
Hypertension
Oral, 1 tablet (50 mg spironolactone + 5 mg bendroflumethiazide) once daily. Maximum 2 tablets per day.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Terminal elimination half-life: 18-24 hours (mean 20 h); clinically, requires 5-7 days to reach steady state; prolonged in renal impairment (Cr Cl <30 m L/min: up to 40 h) and in elderly.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Hydroflumethiazide: not extensively metabolized, mainly excreted unchanged in urine. Reserpine: extensively metabolized in the liver via hydrolysis and conjugation, with metabolites excreted in urine and feces.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Primarily renal (65-75% as unchanged drug); biliary/fecal (20-30%) with enterohepatic recirculation; minor metabolism via CYP3A4 to inactive metabolites.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
98% bound to albumin and α1-acid glycoprotein; binding is concentration-independent; altered in hypoalbuminemia.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
0.15-0.25 L/kg (approx. 10-18 L in 70 kg adult); indicates moderate tissue distribution; Vd increased in hypertension (0.3 L/kg) and decreased in heart failure.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral: 85-95% due to extensive absorption and minimal first-pass metabolism; food delays absorption but does not reduce extent; IV and IM: 100%.
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
Contraindicated if GFR <30 m L/min. If GFR 30-50 m L/min, reduce dose to half tablet daily and monitor potassium; avoid if potassium >5.5 mmol/L.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Contraindicated in Child-Pugh class C. In class A or B, use with caution; start at half tablet daily and monitor hepatic function.
Child-Pugh Class B or C: contraindicated; use not recommended.
Not recommended for children under 18 years due to lack of safety data.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Start at half tablet daily (25 mg spironolactone + 2.5 mg bendroflumethiazide). Monitor renal function, electrolytes, and blood pressure closely. Avoid if creatinine clearance <30 m L/min.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
Reserpine may cause mental depression. Therapy should be discontinued at the first sign of depression (e.g., despondency, early morning insomnia, loss of appetite, impotence). Depressive reactions are more common in patients with a history of depression.
None
Electrolyte imbalance (hypokalemia, hyponatremia), hypotension, drowsiness/sedation, depression risk, exacerbation of peptic ulcer or ulcerative colitis, use caution in renal/hepatic impairment, and avoid abrupt discontinuation (reserpine may cause withdrawal syndrome).
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Hypersensitivity to thiazides, reserpine, or sulfonamides; anuria or severe renal impairment; history of mental depression; active peptic ulcer; ulcerative colitis; pheochromocytoma; electroconvulsive therapy; concurrent MAO inhibitor therapy.
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid high-sodium foods as they may reduce antihypertensive effect. Limit alcohol intake due to additive blood pressure lowering and dizziness risk. Ensure adequate potassium intake (e.g., bananas, oranges) unless contraindicated by renal function.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
First trimester: Limited human data; based on animal studies, possible increased risk of congenital anomalies including cardiovascular and renal defects. Second and third trimesters: Risk of fetal hypotension, decreased placental perfusion, oligohydramnios, and neonatal renal dysfunction or failure. Avoid use in pregnancy unless no alternative.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Excreted into breast milk; M/P ratio not established. Potential for adverse effects in nursing infant (hypotension, bradycardia). Use with caution, monitor infant for signs of hypotension.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
No specific dose adjustment studies; pregnancy may alter pharmacokinetics (increased volume of distribution, decreased plasma protein binding). Monitor therapeutic response and toxicity closely; consider dose titration based on blood pressure.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
SALUTENSIN is a combination of hydrochlorothiazide and reserpine. Monitor for hypokalemia and hyperuricemia due to thiazide; reserpine may cause nasal congestion and depression. Avoid in patients with history of depression or peptic ulcer. Use with caution in renal impairment (Cr Cl <30 m L/min).
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take this medication exactly as prescribed, usually once daily in the morning to avoid nocturia.,Avoid sudden discontinuation; consult your doctor before stopping.,Report symptoms of depression, unusual mood changes, or nasal congestion to your healthcare provider.,This drug may cause dizziness or drowsiness; avoid driving until you know how it affects you.,Monitor for signs of low potassium (muscle cramps, weakness, irregular heartbeat) or high uric acid (joint pain, swelling).
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SALUTENSIN vs ALDORIL D30, answered by our medical review team.
SALUTENSIN is a Antihypertensive Combination that works by Salutensin is a combination of two antihypertensive agents: hydroflumethiazide, a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption; and reserpine, a Rauwolfia alkaloid that depletes catecholamines (norepinephrine, dopamine) from presynaptic nerve terminals by irreversibly blocking vesicular monoamine transporter (VMAT), leading to decreased peripheral vasoconstriction and heart rate.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SALUTENSIN and ALDORIL D30 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SALUTENSIN is: Oral, 1 tablet (50 mg spironolactone + 5 mg bendroflumethiazide) once daily. Maximum 2 tablets per day.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SALUTENSIN and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SALUTENSIN is classified as Category C. First trimester: Limited human data; based on animal studies, possible increased risk of congenital anomalies including cardiovascular and renal defects. Second and third trimester. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.